Nabriva Therapeutics (Nabriva Therapeutics) Days Payable : 105.61 (As of Jun. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Nabriva Therapeutics Days Payable?

Nabriva Therapeutics's average Accounts Payable for the three months ended in Jun. 2023 was $10.50 Mil. Nabriva Therapeutics's Cost of Goods Sold for the three months ended in Jun. 2023 was $9.07 Mil. Hence, Nabriva Therapeutics's Days Payable for the three months ended in Jun. 2023 was 105.61.

The historical rank and industry rank for Nabriva Therapeutics's Days Payable or its related term are showing as below:

NBRVF' s Days Payable Range Over the Past 10 Years
Min: 62.6 Med: 951.22 Max: 20797.18
Current: 66.88

During the past 10 years, Nabriva Therapeutics's highest Days Payable was 20797.18. The lowest was 62.60. And the median was 951.22.

NBRVF's Days Payable is ranked worse than
66.53% of 714 companies
in the Biotechnology industry
Industry Median: 147.95 vs NBRVF: 66.88

Nabriva Therapeutics's Days Payable increased from Jun. 2022 (27.15) to Jun. 2023 (105.61). It may suggest that Nabriva Therapeutics delayed paying its suppliers.

Nabriva Therapeutics Days Payable Historical Data

The historical data trend for Nabriva Therapeutics's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nabriva Therapeutics Days Payable Chart

Nabriva Therapeutics Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Days Payable

Get a 7-Day Free Trial

20,797.18

1,801.65

100.79

62.60

Nabriva Therapeutics Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Days Payable	Get a 7-Day Free Trial															27.15	51.33	26.03	127.57	105.61

Competitive Comparison of Nabriva Therapeutics's Days Payable

For the Biotechnology subindustry, Nabriva Therapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nabriva Therapeutics's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nabriva Therapeutics's Days Payable distribution charts can be found below:

* The bar in red indicates where Nabriva Therapeutics's Days Payable falls into.

Nabriva Therapeutics Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Nabriva Therapeutics's Days Payable for the fiscal year that ended in Dec. 2022 is calculated as

	Days Payable (A: Dec. 2022 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2021 )	+	Accounts Payable (A: Dec. 2022 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2022 )	*	Days in Period
=	( (4.372	+	5.431)	/	2 )	/	28.581	*	365
=	4.9015					/	28.581	*	365
=	62.60

Nabriva Therapeutics's Days Payable for the quarter that ended in Jun. 2023 is calculated as:

	Days Payable (Q: Jun. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Mar. 2023 )	+	Accounts Payable (Q: Jun. 2023 ))	/	count )	/	Cost of Goods Sold (Q: Jun. 2023 )	*	Days in Period
=	( (6.978	+	14.026)	/	2 )	/	9.074	*	365 / 4
=	10.502					/	9.074	*	365 / 4
=	105.61

Nabriva Therapeutics Days Payable Related Terms

Thank you for viewing the detailed overview of Nabriva Therapeutics's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Nabriva Therapeutics (Nabriva Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nabriva Therapeutics PLC (OTCPK:NBRVF) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

N/A

Address

Alexandra House, Office 225/227, The Sweepstakes, Dublin, IRL, 4

Website

https://www.nabriva.com

Nabriva Therapeutics PLC is a clinical stage biopharmaceutical company. Nabriva is engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The company has developed a product candidate, XENLETA, a semi-synthetic pleuromutilin antibiotic that is the first in its class for oral and IV administration in humans. XENLETA is designed to inhibit the synthesis of a specific protein on the bacterial ribosome. It operates in one reportable segment, which comprises the research and development of novel anti-infective agents to treat serious infections. The firm has commercial rights to two approved products, SIVEXTRO and XENLETA, as well as one development product candidate, CONTEPO.

Executives

Hogan H Michael Iii	officer: Chief Executive Officer	C/O 3D SYSTEMS, 26081 AVENUE HALL, VALENCIA CA 91355
David Maggio	officer: Chief Financial Officer	15950 N. DALLAS PARKWAY, SUITE 600, DALLAS TX 75248
Mark Corrigan	director
Broom Colin Md	officer: Chief Executive Officer	119 FRINGETREE DRIVE, WEST CHESTER PA 19380
Stephen W Webster	director	C/O OPTIMER PHARMACEUTICALS, INC, 101 HUDSON STREET, SAN DIEGO CA 07302
Daniel D Burgess	director	C/O HOLLIS-EDEN PHARMACEUTICALS, 4435 EASTGATE MALL STE.400, SAN DIEGO CA 92121
Carrie L. Bourdow	officer: Director	C/O TREVENA, INC., 1018 WEST 8TH AVENUE, SUITE A, KING OF PRUSSIA PA 19406
Rowland Charles A Jr	director	3338 LANCASHIRE RD, FURLONG PA 18925
Theodore R Schroeder	officer: Chief Executive Officer	12481 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130
J. Christopher Naftzger	officer: General Counsel and Corp Sec	633 LOWTHER ROAD, LEWISBERRY PA 17339
Christine J. Guico-pabia	officer: Chief Medical Officer	C/O NABRIVA THERAPEUTICS PLC, 414 COMMERCE DRIVE, SUITE 120, FORT WASHINGTON PA 19034
Lisa Dalton	director	3737 MARKET STREET, SUITE 1300, PHILADELPHIA PA 19104
Daniel Dolan	officer: Chief Financial Officer	C/O NABRIVA THERAPEUTICS PLC, 1000 CONTINENTAL DRIVE, SUITE 600, KING OF PRUSSIA PA 19406
Francesco Maria Lavino	officer: Chief Commercial Officer	1000 CONTINENTAL DRIVE, SUITE 600, KING OF PRUSSIA PA 19406
Robert Crotty	officer: General Counsel & Corp Sec.	1301 2ND AVE, SEATTLE WA 98101